Fortress Biotech, Inc. (FBIO) Key Metrics
FBIO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $62.4M
- Enterprise value
- −$65.2M
- P/E (TTM)
- 0.7
- Forward P/E
- 1.2
- PEG ratio
- —
- Price / sales
- 0.9 10-yr median 0.7
- Price / book
- 0.5 10-yr median 1.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.25
FBIO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsFBIO valuation Price multiples at each fiscal year-end price.
FBIO returns How much profit the business earns on the capital it uses.
FBIO per-share figures Results divided by the shares outstanding at year-end.
FBIO financial health Debt, liquidity and how easily interest is covered.
FBIO efficiency & capital use Working capital cycle and where the cash goes.
FBIO valuation history
FBIO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
FBIO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
FBIO cash returned to shareholders
FBIO price vs earnings per share
FBIO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $130.9M | $42.2M | $24.4M | — | — | — | — | — | — | — |
| Enterprise value | $125.8M | $60.9M | $28.1M | — | — | — | — | — | — | — |
| P/E ratio | 19.2 | — | — | — | — | — | — | — | — | — |
| Price / sales | 2.1 | 0.7 | 0.3 | — | — | — | — | — | — | — |
| Price / book | 2.6 | 1.9 | 1.1 | — | — | — | — | — | — | — |
| EV / sales | 2.0 | 1.1 | 0.3 | — | — | — | — | — | — | — |
| Earnings yield | 5.2% | −109.0% | −248.4% | — | — | — | — | — | — | — |
| Free cash flow yield | −50.3% | −225.6% | −558.4% | — | — | — | — | — | — | — |
| Dividend yield | 0.5% | 11.2% | 35.9% | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.7% | 11.2% | 37.6% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $3.66 | $2.03 | $3.01 | $9.90 | $3.75 | $4.75 | $3.85 | $1.29 | $5.99 | $4.05 |
| Per share | ||||||||||
| Revenue per share | $1.77 | $2.77 | $10.42 | — | — | — | — | — | — | — |
| Earnings per share | $0.19 | −$2.21 | −$7.48 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.84 | −$3.86 | −$15.81 | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.84 | −$4.58 | −$16.81 | — | — | — | — | — | — | — |
| Cash per share | $2.22 | $2.76 | $9.98 | — | — | — | — | — | — | — |
| Book value per share | $1.39 | $1.09 | $2.78 | — | — | — | — | — | — | — |
| Tangible book value per share | $0.62 | −$0.44 | $0.28 | — | — | — | — | — | — | — |
| Dividends per share | $0.02 | $0.23 | $1.08 | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.72 | $1.00 | — | — | — | — | — | — | — |
| Debt per share | $2.08 | $3.65 | $10.44 | — | — | — | — | — | — | — |
| Shares outstanding | 35.8M | 20.8M | 8.1M | — | — | — | — | — | — | — |
| Change in shares outstanding | +72.0% | +156.2% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 18.8% | −203.2% | −188.7% | −115.1% | −61.9% | −73.5% | −284.7% | −309.2% | −146.9% | −89.8% |
| Return on invested capital (ROIC) | −128.7% | −257.6% | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | 4.1% | −29.5% | −26.3% | −25.1% | −17.7% | −16.6% | −21.8% | −43.5% | −32.1% | −38.1% |
| Return on tangible assets | 4.3% | −40.9% | −41.2% | −32.4% | −16.9% | −14.6% | −18.2% | −60.3% | −31.5% | −40.9% |
| Free cash flow margin | −104.0% | −165.0% | −161.3% | −240.9% | −193.2% | −199.2% | −284.9% | −402.5% | −48.4% | −341.7% |
| Income quality (OCF / net income) | −9.65 | — | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $74.3M | $76.0M | $84.7M | $127.3M | $75.0M | $89.1M | $115.1M | $79.5M | $62.5M | $28.2M |
| Cash & short-term investments | $79.4M | $57.3M | $80.9M | $178.3M | $305.7M | $233.4M | $136.9M | $83.1M | $131.0M | $91.7M |
| Net debt | −$5.1M | $18.7M | $3.7M | −$50.9M | −$230.8M | −$144.3M | −$21.7M | −$3.6M | −$68.5M | −$63.5M |
| Debt / equity | 1.49 | 3.34 | 3.76 | 3.05 | 0.69 | 0.89 | 4.39 | 42.93 | 1.19 | 0.73 |
| Debt / assets | 0.40 | 0.53 | 0.51 | 0.43 | 0.19 | 0.27 | 0.51 | 0.56 | 0.25 | 0.17 |
| Current ratio | 2.49 | 1.27 | 1.38 | 1.80 | 3.43 | 5.14 | 3.43 | 2.00 | 2.56 | 1.94 |
| Quick ratio | 2.30 | 1.06 | 1.26 | 1.69 | 3.33 | 5.11 | 3.41 | 1.99 | 2.56 | 1.93 |
| Interest coverage | -8.1 | -11.1 | -11.4 | -14.9 | -12.3 | -6.2 | -9.4 | -11.6 | -11.7 | -17.8 |
| Working capital | $74.1M | $19.0M | $32.1M | $102.7M | $245.4M | $214.4M | $110.6M | $55.6M | $111.7M | $53.1M |
| Invested capital | $44.8M | $41.4M | $26.3M | −$9.2M | −$122.1M | −$43.9M | $4.5M | −$1.8M | −$15.9M | −$25.0M |
| Tangible asset value | $34.6M | −$33.5M | −$18.7M | $22.8M | $213.3M | $182.4M | $65.2M | $18.3M | $86.6M | $46.9M |
| Net current asset value | $476,000 | −$55.5M | −$48.9M | −$13.8M | $175.8M | $129.7M | $2.4M | −$10.0M | $57.7M | $21.9M |
| Graham number | $2.45 | — | — | — | — | — | — | — | — | — |
| Graham net-net per share | −$0.47 | −$3.54 | −$8.43 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | $664,000 | $4.7M | $8.8M | $8.8M | $8.8M | $6.8M | $2.6M | $2.3M | $299,000 | $299,000 |
| Share buybacks (net) | $265,000 | $0 | $400,000 | $1.2M | $0 | $70,000 | $24,000 | $234,000 | $0 | $0 |
| Dividend payout ratio | 9.7% | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 0.0% | 26.0% | 9.6% | 4.0% | 23.8% | 15.7% | 25.6% | 34.8% | 2.9% | 63.7% |
| Capex / depreciation | 0.00 | 3.36 | 1.35 | 0.33 | 2.41 | 1.35 | 2.02 | 4.54 | 4.32 | 9.32 |
| Stock-based compensation / revenue | 45.4% | 56.6% | 20.1% | 30.3% | 28.3% | 29.5% | 36.0% | 55.8% | 7.5% | 73.6% |
| R&D / revenue | 18.8% | 98.6% | 125.5% | 178.1% | 187.3% | 140.6% | 222.0% | 325.1% | 28.0% | 213.2% |
| SG&A / revenue | 152.4% | 152.1% | 118.0% | 150.1% | 126.2% | 134.1% | 151.8% | 198.5% | 38.9% | 199.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 116.4 | 81.6 | 94.4 | 125.6 | 128.6 | 156.4 | 99.2 | 140.2 | 19.8 | 59.2 |
| Days of inventory on hand | 209.8 | 215.3 | 194.2 | 142.4 | 64.1 | 28.3 | 26.6 | 25.3 | 0.4 | 3.3 |
| Days payables outstanding | 400.1 | 580.8 | 733.8 | 620.7 | 334.7 | 268.4 | 483.6 | 830.1 | 27.4 | 258.6 |
| Cash conversion cycle (days) | -73.9 | -283.8 | -445.2 | -352.7 | -142.0 | -83.7 | -357.8 | -664.6 | -7.2 | -196.2 |
| Receivables turnover | 3.14 | 4.47 | 3.86 | 2.91 | 2.84 | 2.33 | 3.68 | 2.60 | 18.44 | 6.17 |
| Payables turnover | 0.91 | 0.63 | 0.50 | 0.59 | 1.09 | 1.36 | 0.75 | 0.44 | 13.31 | 1.41 |
| Inventory turnover | 1.74 | 1.69 | 1.88 | 2.56 | 5.70 | 12.91 | 13.72 | 14.43 | 862.04 | 111.81 |
| Asset turnover | 0.38 | 0.37 | 0.37 | 0.22 | 0.19 | 0.16 | 0.20 | 0.14 | 0.90 | 0.11 |
| Average receivables | $20.2M | $12.9M | $21.9M | $26.1M | $24.2M | $19.5M | $10.0M | $10.3M | $10.2M | $2.7M |
| Average payables | $22.9M | $33.2M | $46.0M | $52.3M | $29.4M | $10.7M | $14.0M | $13.9M | $12.1M | $8.0M |
| Average inventory | $12.0M | $12.3M | $12.2M | $12.0M | $5.6M | $1.1M | $767,500 | $424,500 | $187,000 | $101,500 |
| Intangibles / total assets | 14.9% | 22.1% | 12.1% | 9.2% | 3.2% | 4.4% | 3.3% | 1.0% | 13.8% | 21.1% |
Computed from FBIO's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
FBIO valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Fortress Biotech traded at 19.2 times earnings. Based on the latest twelve months, the trailing P/E is 0.7 and the forward P/E is 1.2. Fortress Biotech earned a return on equity of 18.8% and a return on invested capital of −128.7% in fiscal 2025. It ended the year with $74.3 million of debt and $79.4 million in cash and short-term investments, a net cash position of $5.1 million. It returned $0.9 million to shareholders: $0.7 million in dividends and $0.3 million in share buybacks.
See the FBIO income statement, the FBIO chart for price history, or the FBIO stock overview for the latest quote and news.
FBIO key metrics FAQ
What is Fortress Biotech's P/E ratio?
Fortress Biotech's trailing P/E ratio is 0.7 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 1.2. At the end of fiscal 2025 it was 19.2.
What is Fortress Biotech's return on equity?
Fortress Biotech's return on equity (ROE) was 18.8% in fiscal 2025: net income of $6.8 million on average shareholders' equity of $36.3 million.
What is Fortress Biotech's ROIC?
Fortress Biotech's return on invested capital was −128.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Fortress Biotech have?
Fortress Biotech had total debt of $74.3 million at the end of fiscal 2025, a debt-to-equity ratio of 1.49 and more cash than debt.
What is Fortress Biotech's dividend yield?
Fortress Biotech paid $0.7 million in dividends in fiscal 2025 ($0.02 per share), a payout ratio of 9.7%.
Does Fortress Biotech buy back its shares?
Yes. Fortress Biotech spent $0.3 million on net share repurchases in fiscal 2025 Shares outstanding changed +72.0% over the year, to 35.8M..
What is Fortress Biotech's free cash flow yield?
Fortress Biotech generated -$65.8 million of free cash flow in fiscal 2025, a free cash flow yield of −50.3% on its market value at year-end ($130.9 million).
What is Fortress Biotech's current ratio?
Fortress Biotech's current ratio was 2.49 at the end of fiscal 2025: current assets were 2.49 times current liabilities.